Guideline for Management of Functional Abdominal Pain in Adults without Alarm Features

Diagnostic Evaluation

• Diagnose functionally based on chronic or recurrent abdominal pain lasting ≥ 3 months without a structural cause, using limited investigations (CBC, celiac serology, plain abdominal radiography during acute episodes) to exclude obvious pathology. 1
• Reserve advanced imaging (small‑bowel series, CT) only for patients whose symptom pattern changes, who develop severe symptoms, or who have specific demographic risk factors. 1

Therapeutic Relationship & Patient Education

• Explain that functional abdominal pain is a disorder of gut‑brain interaction involving altered pain processing, visceral hypersensitivity, and central sensitization—not a purely psychological condition. 2
• Build a collaborative therapeutic alliance; continuous clinician involvement is foundational to successful outcomes. [2][1]
• Avoid repetitive testing after a functional diagnosis, as it reinforces illness behavior and adds unnecessary cost without clinical benefit. 1

Pharmacologic Management

First‑Line Neuromodulators

• Initiate low‑dose tricyclic antidepressants (amitriptyline 10 mg at bedtime, titrated every 2–3 weeks to 30–50 mg) as the primary medication for abdominal pain. Analgesic effects typically appear within 1–3 weeks via neuromodulation of central pain pathways. [3][1]
• Alternative neuromodulators (SNRIs such as duloxetine or venlafaxine, or mirtazapine) may be used, but the strongest evidence supports TCAs. 3

Adjunctive Antispasmodic Therapy

• Anticholinergic antispasmodics (e.g., hyoscyamine, dicyclomine) can be added when pain is clearly meal‑related or cramping in nature. They provide symptomatic relief but do not address underlying sensitization, making them suitable for mild symptoms or as adjuncts. 1

Psychological & Behavioral Interventions

• Offer cognitive‑behavioral therapy, gut‑directed hypnotherapy, or mindfulness‑based stress reduction for patients with moderate‑to‑severe symptoms, impaired quality of life, or inadequate response to initial pharmacotherapy. [2][3]1
• These interventions target pain catastrophizing, maladaptive coping, and central pain amplification, and have demonstrated sustained benefits for abdominal pain and overall function. [2][1]
• They are most effective when symptoms are linked to identifiable stressors, co‑existent anxiety/depression, or when the pain course is shorter with waxing‑waning patterns. 1

Lifestyle and Dietary Strategies

• Encourage regular aerobic physical activity, which improves pain symptoms and quality of life by reducing visceral hypersensitivity. 2
• Provide education on sleep hygiene, mindful eating, and stress‑management techniques to boost self‑efficacy and symptom control. 2
• Avoid overly restrictive diets; instead, use systematic trial‑and‑error to identify and moderately limit specific trigger foods. [2][4]
• Refer patients with overlapping bowel symptoms (e.g., bloating, altered stool pattern) to a gastroenterology dietitian; a low‑FODMAP diet may be appropriate when delivered by a trained dietitian to prevent nutritional inadequacy. 2
• Standard dietary advice includes adequate fiber intake (~25 g/day), though evidence for direct pain reduction is mixed. 1

Management of Refractory Cases

• For patients not responding to first‑line TCA therapy, consider combination neuromodulation (e.g., TCA + SNRI or gabapentinoid) while monitoring for serotonin syndrome. 3
• Refer to a multidisciplinary pain‑management program (gastroenterology, psychology, dietetics, pain specialists) for severe, refractory symptoms with significant functional impairment. [2][3]1
• Mood stabilizers (gabapentin, pregabalin) or atypical antipsychotics (quetiapine) should be used only after psychiatric consultation in intractable cases. 3

Medications to Avoid

• Opioids must never be prescribed for functional abdominal pain; they worsen dysmotility, induce hyperalgesia, risk narcotic‑bowel syndrome, and provide no long‑term benefit. [3][4]
• Benzodiazepines should be avoided due to high dependence risk and lack of efficacy for visceral pain. 3
• Chronic cyclizine use should be discontinued because of addiction potential and risk of venous damage. 4

Referral and Escalation Criteria

• Refer to gastroenterology when diagnostic uncertainty persists, symptoms remain refractory after 6–8 weeks of appropriate first‑line therapy, or the patient requests specialist input. [2][1]
• Refer to gastropsychology or psychiatry for moderate‑to‑severe depression/anxiety, suicidal ideation, suspected eating disorders, or concerns about medication misuse. 2
• Re‑evaluate patients 3–6 weeks after initiating treatment to assess response and adjust the management plan accordingly. 1

Common Pitfalls to Avoid

• Do not pursue exhaustive imaging or endoscopic evaluation in young patients without alarm features, as this delays effective treatment and reinforces illness behavior. 1
• Do not use low‑dose TCAs (10–30 mg) to treat comorbid major depression or anxiety; therapeutic‑dose SSRIs (e.g., sertraline 50–200 mg) are required for psychiatric benefit. 3
• Do not implement restrictive diets without dietitian supervision, especially in patients with weight loss, nutritional deficiency, or psychological comorbidities suggesting an eating disorder. [2][4]
• Avoid surgical interventions for functional abdominal pain; they carry high risk of iatrogenic harm without addressing the underlying pain mechanism. 4

Management of Functional Abdominal Pain

Initial Assessment and Diagnosis

• During acute episodes, plain abdominal radiography should be performed to exclude bowel obstruction and other abdominal pathology in patients with functional abdominal pain 5
• Additional testing, such as small bowel series or CT scan, may be needed based on symptom duration, severity, changes in symptom type, and demographic factors in patients with functional abdominal pain 5

Treatment Algorithm Based on Symptom Severity

• The American Gastroenterological Association recommends a structured treatment strategy based on symptom severity, with first-line therapies including antispasmodics for pain-predominant symptoms and tricyclic antidepressants for more severe or frequent pain 5, 6
• For pain-predominant symptoms, antispasmodic medications, particularly those that are anticholinergic, are recommended when symptoms are exacerbated by meals 5
• For diarrhea, Loperamide (2-4 mg, up to four times daily) can be used to reduce loose stools and urgency in patients with functional abdominal pain 5
• For constipation, increased dietary fiber (25 g/day) is recommended, although evidence for pain reduction is mixed 5
• Tricyclic antidepressants at low doses are the mainstay of therapy for functional pain disorders, with analgesic effects occurring at lower doses than required for mood effects, as recommended by the American College of Gastroenterology 6
• For patients with psychological comorbidities, selective serotonin reuptake inhibitors at therapeutic doses can be considered 6, 7
• Combination therapy with different neuromodulators can be considered for severe pain, while monitoring for serotonin syndrome, as suggested by the European Society of Gastrointestinal Motility 8
• Opioids and benzodiazepines should be avoided due to high risk of dependence and potential to worsen symptoms long-term, as recommended by the American Gastroenterological Association 9

Psychological Interventions

• Psychological treatments should be initiated when symptoms are severe enough to impair health-related quality of life, as recommended by the American Psychological Association 5
• Evidence-based psychological approaches include cognitive-behavioral therapy, gut-directed hypnotherapy, mindfulness-based stress reduction, and psychodynamic interpersonal therapy, as suggested by the European Society of Gastrointestinal Motility 6, 10, 11

Dietary Approaches

• Standard dietary advice should be provided for patients with mild gastrointestinal symptoms, as recommended by the Academy of Nutrition and Dietetics 7
• For moderate to severe symptoms, a low FODMAP diet with proper nutritional guidance from a dietitian can be considered, as suggested by the American Gastroenterological Association 7, 9

Special Considerations

• Patients with functional abdominal pain should be screened for underlying psychiatric disturbances, as untreated mood disorders adversely affect treatment response, as recommended by the American Psychiatric Association 11
• Invasive interventions should be avoided in patients with functional symptoms, especially those with pain-predominant presentations without objective features of biochemical disturbance, as recommended by the European Society of Gastrointestinal Motility 12

Treatment Monitoring

• Patients should be reevaluated after 3-6 weeks of initial treatment, as recommended by the American Gastroenterological Association 5
• If treatment is unsuccessful or further evaluation seems needed, additional studies based on symptom subtype can be considered, as suggested by the American College of Gastroenterology 5
• For patients with severe and refractory symptoms, referral to a multidisciplinary pain center may be beneficial, as recommended by the American Pain Society 5